Locus Biosciences
Locus Biosciences is a developer of precision antimicrobial therapeutics for infectious diseases and inflammatory conditions. The company has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria, enabling the development of targeted antimicrobials that kill harmful bacteria while preserving beneficial microbiome. This CRISPR-based approach offers an alternative to…
Funding snapshot
About
Locus Biosciences is a developer of precision antimicrobial therapeutics for infectious diseases and inflammatory conditions. The company has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria, enabling the development of targeted antimicrobials that kill harmful bacteria while preserving beneficial microbiome. This CRISPR-based approach offers an alternative to traditional antibiotics, addressing the growing crisis of antimicrobial resistance. Locus Biosciences' technology programs target urinary tract infections, Clostridioides difficile infections, and other bacterial diseases. Founded in 2015 and headquartered in Raleigh, North Carolina, Locus Biosciences has raised approximately $67.3 million at the Series B stage from investors including Artis Ventures, Viking Global Investors, Tencent, Johnson & Johnson Innovation, Illumina, Hercules Capital, Abstract Ventures, NCBiotech, HHS, Starlight Ventures, TechAccel, and Codon Capital.
Business model
Infectious Diseases > Drugs > Bacterial > Drug Resistant Infections,
Genomics > Enabling Technologies > Technology Platforms > Gene Editing
Founders & team highlights
Serial Founder
Team background
Company Wise > McKinsey,
College Wise > Cornell University, Duke University
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.